OC CONTRIBUTES TO MAJOR JOURNAL
Oncology Consultants contributed to an important safety study of Nivolumab (Opdivo), published in The Lancet Oncology, March the 1st 2015. This new drug has a meaningful and manageable safety profile in previously treated patients with advanced, refractory, squamous nonsmall cell lung cancer. The FDA approved Nivolumab, a fully human IgG4 PD-1 immune check inhibitor antibody, for this indication.
The Doctors & Staff of Oncology Consultants are pleased to help advance oncology treatments from research to practice through our participation in the Checkmate Protocol. (NCT01721759).